Last fall, the University of Southern California’s Keck School of Medicine sponsored a well-attended program in New York City on Alzheimer’s Disease (“Changing Minds: USC’s Approach to Alzheimer’s”) to discuss the groundbreaking research they are actively pursuing. The program focused on treatments the Alzheimer’s Therapeutic Research Institute (ATRI) was looking to advance. As part of their current research, several clinical trials have been designed by ATRI and they need participation. These trials are available either online or locally in New York City.
They are listed below:
The “ADNI Study” (Alzheimer’s Disease Neuroimaging Initiative) is urgently looking for participants. The research study uses state-of-the-art imaging to monitor brain levels of two proteins—tau and amyloid—both of which are significant indicators of Alzheimer’s disease. Researchers also track cognitive function through computer tests at home, and occasional exams and tests in a doctor’s office. No medication is involved. Eligible participants are between the ages of 55-90 and have memory concerns with or without a diagnosis of early AD or MCI. To learn more or to get started, visit the ADNI3 website.
If you are 50 years of age or older, now is the time to volunteer for the Alzheimer Prevention Trials Webstudy (APT Webstudy) and help us in the fight against Alzheimer’s disease (AD). The APT Webstudy is an online cognitive assessment research study aimed at accelerating the enrollment time for clinical trials designed to prevent AD. The purpose of the webstudy is to develop a large online group of individuals who may be at higher risk for developing Alzheimer’s dementia, and who may be interested in participating in a prevention trial. By volunteering your time to take and share your memory and thinking test results, you will be helping to reduce the time it takes us to conduct our research.
If you or someone you know should be part of the above trials, please join us in the fight against this devastating disease. USC is part of the Alzheimer’s Clinical Trials Consortium (ACTC) which is a clinical trials infrastructure launched in December, 2017 by the National Institutes of health and designed to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias.
Strategic Communications Professional/Content Strategist/Marketing Communications Consultant
